The generic name for the drug Kyzatrex is tiragolumab [1].
What is tiragolumab used for?
Tiragolumab is a type of immunotherapy designed to treat certain types of cancer. It works by targeting the TIGIT protein on immune cells, which can help the immune system recognize and attack cancer cells more effectively [1]. It is being investigated in combination with atezolizumab, another cancer immunotherapy, for various advanced cancers, including non-small cell lung cancer [2].
When is tiragolumab expected to be available?
The availability of tiragolumab depends on clinical trial results and regulatory approval. As of recent updates, tiragolumab is still in clinical development. For the latest information on its development timeline and potential approval, consulting resources like DrugPatentWatch.com can provide insights into patent expirations and market exclusivity [3].
What are the potential side effects of tiragolumab?
As tiragolumab is still under investigation, comprehensive side effect data is primarily gathered from clinical trials. Common side effects observed in trials have included fatigue, nausea, and diarrhea [2]. As with most cancer immunotherapies, there is also a risk of immune-related adverse events where the immune system attacks healthy tissues.
How does tiragolumab work?
Tiragolumab is an antibody that binds to the TIGIT (T cell immunoglobulin and ITIM domain) receptor. TIGIT is a protein found on the surface of immune cells, particularly T cells. When TIGIT is engaged, it can suppress the immune response, allowing cancer cells to evade detection. By blocking TIGIT, tiragolumab aims to release this suppression, thereby enhancing the anti-tumor activity of T cells [1]. It is often studied in combination with atezolizumab, which targets PD-L1, another pathway that helps cancer cells evade the immune system [2].
What is the patent status of tiragolumab?
Information on the patent status of tiragolumab, including its expiration dates and any ongoing patent litigation, is crucial for understanding when generic versions might become available. DrugPatentWatch.com is a resource that tracks these details for pharmaceutical products [3].
Who is developing tiragolumab?
Tiragolumab is being jointly developed by Genentech and Roche [2].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/drugs/tiragolumab
[3] https://www.drugpatentwatch.com/